189 related articles for article (PubMed ID: 16110135)
1. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.
Tas F; Oguz H; Argon A; Duranyildiz D; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(3):241-6. PubMed ID: 16110135
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
4. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
Wang W; Zhang MH; Yu Y; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between tumor necrosis factor alpha, interleukin-6 and erythropoietin in children's with chronic anemia and influence of recombinant human tumor necrosis factor alpha on erythropoietin gene expression].
Zhai XW; Wu Y; Gu XF; Lu FJ
Zhonghua Er Ke Za Zhi; 2004 Jan; 42(1):62-5. PubMed ID: 14990112
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
7. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract][Full Text] [Related]
11. [Pattern of blood levels of erythropoietin and proinflammatory cytokines in patients with anemia of chronic disorders secondary to infection].
Poveda Gómez F; Camacho Siles J; Quevedo Morales E; Fernández Zamorano A; Codoceo Alquinta R; Arnalich Fernández F; Sempere Alcocer M
An Med Interna; 2001 Jun; 18(6):298-304. PubMed ID: 11503575
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
13. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
16. A study on biochemical facet of anemia in cancers: A strong link between erythropoietin and tumor necrosis factor alpha in anemic cancer patients.
Kalyani P; Jamil K
Indian J Cancer; 2015; 52(1):127-32. PubMed ID: 26838000
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor necrosis factor-alpha and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia.
Capalbo S; Battista C; Delia M; Ciancio A; De Santis G; Dargenio M; Diomede D; Liso V
Acta Haematol; 2002; 108(2):84-9. PubMed ID: 12187026
[TBL] [Abstract][Full Text] [Related]
18. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
19. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
Mouawad R; Benhammouda A; Rixe O; Antoine EC; Borel C; Weil M; Khayat D; Soubrane C
Clin Cancer Res; 1996 Aug; 2(8):1405-9. PubMed ID: 9816314
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
